– DENMARK – Bavarian Nordic A/S (OMX: BAVA) – After having served as chairman of the board of Bavarian Nordic for 20 years, CEO Asger Aamund has announced that he will not seek re-election at the upcomingGeneral Meeting on April 24, 2014.
The board of directors intends, if re-elected, to nominate Dr. Gerard van Odijkas new chairman of the board of Bavarian Nordic. Dr. van Odijk is a Dutch national, born in 1957. He holds a medical degree from the State University of Utrecht. He is former President and CEO of Teva Pharmaceuticals Europe B.V. and has previously held various senior positions in GlaxoSmithKline. He currently serves as an independent advisor and board member in several international companies. Dr. van Odijk has been member of the board of directors of Bavarian Nordic since 2008.
About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. IMVAMUNE is approved in the European Union under the trade name IMVANEX®.
Bavarian Nordic’s shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.